Table 2.
Summary measures of clinical characteristics and outcomes of patients with secondary oxalate nephropathy (derived from 10 case series entailing 51 patients)
| Variable | No. of studies | No. patients | Weighted mean | 95% CI | I2 index, % |
|---|---|---|---|---|---|
| Patient characteristics | |||||
| Age, yr | 10 | 51 | 56.4 | 48.6−64.3 | 94 |
| Men | 10 | 51 | 59.0 | 42.0−75.0 | 16 |
| White | 10 | 51 | 81.0 | 66.0−90.0 | 0 |
| Native kidney | 9 | 48 | 85.0 | 70.0−93.0 | 0 |
| Kidney allograft | 2 | 3 | 15.0 | 7.0−31.0 | 0 |
| Attributed cause | |||||
| Increased intake of oxalate precursors | 10 | 51 | 20.2 | 9.9−36.6 | 4 |
| Increased oxalate availability | 10 | 51 | 88.3 | 75.1−95.0 | 0 |
| Serum creatinine, mg/dl | |||||
| Baseline | 10 | 51 | 1.3 | 1.1−1.5 | 92 |
| At presentation | 8 | 37 | 4.9 | 3.4−6.4 | 98 |
| Peak | 10 | 51 | 4.6 | 3.0−6.2 | 97 |
| End of follow-up | 6 | 32 | 2.7 | 2.2−3.1 | 22 |
| Urinary findings | |||||
| Proteinuria | 6 | 33 | 69.0 | 34.0−91.0 | 51 |
| Hematuria | 3 | 16 | 32.0 | 14.0−58.0 | 0 |
| Oxalate crystals | 3 | 16 | 26.0 | 10.0−53.0 | 0 |
| Urinary oxalate, mg/d | 6 | 25 | 85.4 | 68.7−102.1 | 92 |
| Kidney biopsy findings | |||||
| Tubular injury | 10 | 51 | 71.0 | 44.0−89.0 | 41 |
| Tubular atrophy | 10 | 51 | 69.0 | 43.0−87.0 | 43 |
| Interstitial cellular infiltrate | 10 | 51 | 72.0 | 45.0−89.0 | 43 |
| Glomerular findings | 10 | 51 | 59.0 | 40.0−76.0 | 23 |
| Kidney and patient outcomes | |||||
| Dialysis requirement | 9 | 40 | 55.0 | 38.0−70.0 | 0 |
| Partial recovery | 9 | 40 | 42.0 | 27.0−58.0 | 0 |
| Dialysis dependence | 9 | 40 | 58.0 | 42.0−73.0 | 0 |
| Mortality rate | 9 | 40 | 33.0 | 17.0−55.0 | 15 |
| Duration of follow-up, mo | 8 | 38 | 12.9 | 5.9−19.9 | 75 |
CI, confidence interval.
Values are %, unless otherwise noted.